1-800-710-4674

Blog Post

Return to News

Feature Story

 
acute myeloid leukemia treatment

OHC Doctor Is Leading an Evaluation of a Potential New Treatment for Acute Myeloid Leukemia, the Most Common Blood Cancer in Adults

OHC, Specialists in Cancer and Blood Disorders, Blogs, 0 comments
November 12, 2019

 

Following their ongoing commitment to provide patients with the latest treatment options, doctors at OHC are evaluating another new treatment option for patients diagnosed with acute myeloid leukemia (AML). This treatment is for AML patients who are ineligible to receive standard chemotherapy due to existing medical conditions.

“Patients with AML, especially older patients, often have conditions such as heart disease, kidney failure, hepatitis, stroke, and others. These conditions often prohibit the use of standard chemotherapy because the strength of the drugs is too hard on organs that have been weakened due to these medical conditions,” said OHC’s E. Randolph Broun, MD, medical oncologist, hematologist and transplant specialist.

For these patients, OHC is evaluating a new combination of chemotherapy drugs that may provide another option for these patients. “The drugs being evaluated aren’t as intense and therefore easier on the body’s organs,” said Dr. Broun who is the principal investigator for the clinical trial.

Two chemotherapy drug combinations are being evaluated in the OHC trial. One combination is venetoclax plus azacitidine. The other combination is venetoclax plus decitabine. Venetoclax is a chemotherapy drug that slows or stops the growth of cancer cells. The other two chemotherapy drugs “switch on” the genes that stop the cancer cells growing and dividing. When combined, they have a dual attack on the cancer yet are mild enough for patients with other medical conditions. And they can be administered in a doctor’s office outpatient setting.

“We decided to participate in clinical trials like this one because the treatment options for these patients are limited due to their overall health,” said Dr. Broun. “We hope the results of this trial are promising and will lead to an FDA approval, thus providing all AML patients with this additional treatment option. In the meantime, patients here in this region who meet requirements can access the treatment now through our clinical trial.”

OHC has been a longtime participant in clinical trials due their commitment to providing the most advanced treatment options for cancer patients. OHC’s nationally-recognized clinical trials program offers patients early access to promising new treatments before they are available to the public. For a list of open trials or for a second opinion, please visit here or call 1-800-710-4674.

 
 

Leave a Reply

Your email address will not be published. Required fields are marked *